Immunocore Holdings plc IMCR

AI giants are pouring hundreds of billions into new health focused tools, and hospitals, insurers and drug makers are under pressure to show they can use that firepower to cut costs and ease staffing strains. That puts high quality healthcare stocks with strong balance sheets and solid execution in a sweet spot. This article highlights three of the strongest options from our curated healthcare shortlist. The three healthcare stocks profiled below are just a small sample, and the full screen...

Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma Topline overall survival data expected as early as end of 2026 (OXFORDSHIRE, England & CONSHOHOCKEN, PA & ROCKVILLE, MD, US, 14 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve

Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 1 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in September.

Immunocore Holdings plc has reported past second-quarter 2026 results showing revenue of US$115.93 million, with net loss narrowing to US$0.808 million, while first-half 2026 revenue reached US$222.60 million and shifted from a prior-period loss to net income of US$12.16 million. Alongside these figures, management highlighted Kimtrak’s first-half net revenue of US$223 million and five-year survival data in metastatic uveal melanoma, underscoring the therapy’s clinical and commercial...

Immunocore reports 16% revenue growth for Kimtrak, advances three Phase 3 trials, and maintains a robust $880 million cash position.

Immunocore reports robust first-half revenue, advances multiple Phase 3 trials, and maintains a strong cash position despite expected headwinds.

Immunocore reports second quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $115.9 million in Q2 2026, growing by 18% year-over-year Enrollment in Phase 3 TEBE-AM trial for previously treated advanced cutaneous melanoma nearing the target of 540 patients – Data could come as early as end of 2026 Oral presentation of five-year overall survival data showing KIMMTRAK doubles likelihood of being alive at five years for patients with HLA-A*02:01 pos

Immunocore to report second quarter 2026 financial results and host call on August 6, 2026 (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 30 July 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report financial results

Immunocore Holdings (NasdaqGS:IMCR) has drawn fresh attention after a recent move in its share price, with the stock up around 21.6% over the past month and 6.2% in the past 3 months. See our latest analysis for Immunocore Holdings. That short term strength, including a 21.6% 1 month share price return and 6.7% 7 day share price return at a latest share price of $33.78, contrasts with a 1 year total shareholder return that is down 2.3% and a 3 year total shareholder return that is down 47.3%...